指南与共识浆细胞疾病

Belantamab Mafodotin相关眼部事件的临床管理实践指南

Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.
指南 / 共识 · Am J Hematol · 2025-07-28

该指南由国际血液科与眼科专家小组基于系统文献综述、临床试验数据及真实世界证据制定,针对复发/难治多发性骨髓瘤患者使用belantamab mafodotin(belamaf)相关眼部事件的识别、监测和管理提出临床建议。眼部事件常见但主要為1-2级角膜上皮病变,几乎均可逆,通过剂量调整、降低给药频率和人工泪液可管理,且剂量调整不影响疗效。

要点

  • belamaf相关眼部事件常见,主要累及角膜上皮,按Keratopathy and Visual Acuity量表多为1-2级,几乎全部患者可逆。
  • 开始belamaf治疗前所有患者应接受眼科专科基线评估;若评估延迟或病情快速进展,可先启动治疗并尽快完成眼科评估。
  • 在第2、3、4周期前应由眼科专科评估;第4周期后治疗医生可结合Vision-Related Anamnestic工具和临床判断决定是否给药或转诊眼科。

核心结论

  • 专家小组制定了belamaf相关眼部事件的管理建议,旨在促进belamaf的临床易用性并改善患者结局。
  • belamaf相关眼部事件主要通过对症剂量调整和降低给药频率以及使用人工泪液进行管理,根据眼部事件调整belamaf剂量与治疗疗效降低无关。

研究设计与样本

  • 指南制定:国际血液科和眼科专家小组基于系统文献综述、临床试验数据、真实世界证据及已发表文献,结合专家集体经验制定推荐。

主要发现

  • belamaf相关眼部事件是治疗常见副作用,影响角膜上皮,按Keratopathy and Visual Acuity量表主要为1级和2级,几乎所有患者可逆。
  • 管理主要包括适当的剂量调整和降低给药频率,以及使用人工泪液。
  • 根据眼部事件调整belamaf剂量与治疗疗效降低无关。

关键数值与推荐

  • 一般所有患者在开始belamaf治疗前应接受眼科专科基线评估。
  • 若获取眼科评估有延迟或患者病情快速进展,应启动治疗并尽快进行眼科评估。
  • 患者应在接下来三次belamaf给药前(即第2、3、4周期前)由眼科专科评估;如有需要可适用本文所述的剂量调整。
  • 第4周期后,治疗医生可使用Vision-Related Anamnestic工具结合临床判断,决定是否给予下一剂belamaf或转诊眼科专科(即患者出现新发视力恶化或眼部事件8周未改善、12周未缓解)。

临床怎么用

  • 开始belamaf治疗前应安排眼科专科基线评估;若评估延迟或病情快速进展,可先启动治疗并尽快完成眼科评估。
  • 第2、3、4周期前应由眼科专科评估,并根据眼部事件按本文所述进行剂量调整。
  • 第4周期后治疗医生可结合Vision-Related Anamnestic工具和临床判断决定是否给药或转诊眼科。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Belantamab mafodotin (belamaf)-containing regimens are effective treatment options for patients with relapsed and/or refractory multiple myeloma. Ocular events are a common adverse effect of belamaf treatment, which can be managed by physicians, following appropriate training, to minimize their impact on the patient. OBJECTIVE: To develop clinical recommendations for the identification, monitoring, and management of ocular events associated with belamaf therapy, and guidance for any required dose modification. EVIDENCE REVIEW: A systematic literature review was conducted and an international group of hematologists and ophthalmologists reviewed clinical trial data, real-world evidence, and published literature on belamaf-associated ocular events. This literature review and the collective experience and expertise of the panel of experts informed the recommendations. FINDINGS: Belamaf-associated ocular events are common side effects of treatment, which are managed primarily with appropriate dose modification and decreased frequency of dosing, as well as the use of artificial tears. These events affect the corneal epithelium, are mainly Grade 1 and 2 per the Keratopathy and Visual Acuity scale and are reversible in almost all patients. In general, before initiating belamaf therapy, all patients should undergo a baseline ophthalmic evaluation with an eye specialist. However, if there are delays in obtaining ophthalmic evaluation, or if a patient is rapidly progressing, treatment should be initiated, and ophthalmic evaluation should be undertaken as soon as possible. Patients should be also evaluated by an eye specialist before administering the next three belamaf doses (i.e., before Cycles 2, 3, and 4); dose modifications, as described in this paper, may apply if required. Importantly, modifying the belamaf dose in response to an ocular event is not associated with any reductions in treatment efficacy. After Cycle 4, the treating physician may use the Vision-Related Anamnestic tool, alongside clinical judgment, to decide whether to administer the next dose of belamaf or to refer the patient to an eye specialist (i.e., if the patient experiences new worsening of vision or if the ocular events have neither improved after 8 weeks nor resolved after 12 weeks). CONCLUSIONS AND RELEVANCE: The expert panel developed recommendations for managing belamaf-associated ocular events, with the aim of contributing to the ease of clinical use of belamaf and improving patient outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Terpos E, Trudel S, Mateos MV, et al. Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events. Am J Hematol. 2025. PMID: 40717676. doi:10.1002/ajh.70015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。